Guggenheim has adjusted its price target for Cabaletta Bio (CABA, Financial), raising it from $23 to $25 while maintaining a Buy rating on the stock. Following insights gained from discussions with the company's leadership after their first-quarter report, Guggenheim highlights Cabaletta's strategy of collaborating with the FDA. This collaboration focuses on an "efficient trial design," which is notably smaller and potentially quicker than its competitors. Additionally, the possibility of receiving a broad label strengthens the firm's confidence in Cabaletta's strategic direction.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Cabaletta Bio Inc (CABA, Financial) is $16.22 with a high estimate of $28.00 and a low estimate of $3.00. The average target implies an upside of 913.89% from the current price of $1.60. More detailed estimate data can be found on the Cabaletta Bio Inc (CABA) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Cabaletta Bio Inc's (CABA, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
